NO20042023L - Kinuklidinderivater fremgangsmate for flemstilling av disse og anvendelse av disse som m2- og/eller m3-muskarinreseptor-inhibitorer - Google Patents

Kinuklidinderivater fremgangsmate for flemstilling av disse og anvendelse av disse som m2- og/eller m3-muskarinreseptor-inhibitorer

Info

Publication number
NO20042023L
NO20042023L NO20042023A NO20042023A NO20042023L NO 20042023 L NO20042023 L NO 20042023L NO 20042023 A NO20042023 A NO 20042023A NO 20042023 A NO20042023 A NO 20042023A NO 20042023 L NO20042023 L NO 20042023L
Authority
NO
Norway
Prior art keywords
kinuclidine
multiplying
receptor inhibitors
derivatives process
muscarin receptor
Prior art date
Application number
NO20042023A
Other languages
English (en)
Norwegian (no)
Inventor
Michel Guyaux
Chimmanamnada U Dinesh
Charles Mioskowski
Luc Quere
Jean-Philippe Starck
Patrice Talaga
Alain Wagner
Matteo ZANDA
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20042023L publication Critical patent/NO20042023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20042023A 2001-10-17 2004-05-14 Kinuklidinderivater fremgangsmate for flemstilling av disse og anvendelse av disse som m2- og/eller m3-muskarinreseptor-inhibitorer NO20042023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01124727 2001-10-17
PCT/EP2002/010644 WO2003033495A1 (en) 2001-10-17 2002-09-23 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors

Publications (1)

Publication Number Publication Date
NO20042023L true NO20042023L (no) 2004-05-14

Family

ID=8178984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042023A NO20042023L (no) 2001-10-17 2004-05-14 Kinuklidinderivater fremgangsmate for flemstilling av disse og anvendelse av disse som m2- og/eller m3-muskarinreseptor-inhibitorer

Country Status (19)

Country Link
US (1) US7361668B2 (is)
EP (1) EP1438309A1 (is)
JP (1) JP2005512974A (is)
KR (1) KR20050030169A (is)
CN (1) CN1571787A (is)
BG (1) BG108683A (is)
BR (1) BR0212983A (is)
CA (1) CA2462980A1 (is)
CZ (1) CZ2004501A3 (is)
HU (1) HUP0401849A3 (is)
IL (1) IL160896A0 (is)
IS (1) IS7186A (is)
MX (1) MXPA04002983A (is)
NO (1) NO20042023L (is)
NZ (1) NZ532283A (is)
PL (1) PL370087A1 (is)
RU (1) RU2004110717A (is)
WO (1) WO2003033495A1 (is)
ZA (1) ZA200402060B (is)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004110717A (ru) * 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
AU2003222738B2 (en) 2002-05-07 2009-09-17 Neurosearch A/S Novel azacyclic ethynyl derivatives
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
PE20050711A1 (es) * 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
PE20050327A1 (es) * 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CN101230061A (zh) * 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
MXPA06004242A (es) * 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008096094A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
AU2008240704A1 (en) * 2007-04-24 2008-10-30 Solvay Pharmaceuticals B.V. Heterocyclic compounds with affinity to muscarinic receptors
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JP2011520905A (ja) 2008-05-15 2011-07-21 ザ・ユニバーシティ・オブ・トレド 向知性剤としてのムスカリンアゴニスト
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2009152392A2 (en) * 2008-06-11 2009-12-17 University Of Toledo Muscarinic agonists for neurological disorders and methods of making the same
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
IN2012DN01453A (is) 2009-08-20 2015-06-05 Novartis Ag
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
CN106518840B (zh) * 2016-11-17 2019-03-01 山东铂源药业有限公司 一种2-氯噻吩-5-甲酸的合成方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
GB9127279D0 (en) * 1991-12-23 1992-02-19 Ici Plc Heterocyclic derivatives
GB9216721D0 (en) * 1992-08-06 1992-09-23 Ici Plc Therapeutic heterocyclic derivatives
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5384462A (en) * 1992-12-08 1995-01-24 Levitt; Roy C. Process and apparatus for localizing a source of charged particles using an electric field
GB9226573D0 (en) * 1992-12-21 1993-02-17 Ici Plc Heterocyclic compounds
JPH08134067A (ja) * 1994-11-11 1996-05-28 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
PL322083A1 (en) * 1995-03-02 1998-01-05 Yamanouchi Pharma Co Ltd Novel derivative of quinuklidine, incorporating a tricyclic system of condensed heteronuclei
HUP0203514A3 (en) 1999-09-28 2004-01-28 Eisai Co Ltd Quinuclidine compounds and drugs containing them and process for preparation the same
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE366248T1 (de) * 2001-03-27 2007-07-15 Eisai R&D Man Co Ltd N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
RU2004110717A (ru) * 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов

Also Published As

Publication number Publication date
KR20050030169A (ko) 2005-03-29
ZA200402060B (en) 2005-03-15
RU2004110717A (ru) 2005-10-20
NZ532283A (en) 2005-06-24
US20050020660A1 (en) 2005-01-27
US7361668B2 (en) 2008-04-22
MXPA04002983A (es) 2004-07-15
JP2005512974A (ja) 2005-05-12
CN1571787A (zh) 2005-01-26
BR0212983A (pt) 2004-10-13
WO2003033495A1 (en) 2003-04-24
EP1438309A1 (en) 2004-07-21
IS7186A (is) 2004-03-18
IL160896A0 (en) 2004-08-31
HUP0401849A3 (en) 2007-05-02
PL370087A1 (en) 2005-05-16
CA2462980A1 (en) 2003-04-24
BG108683A (en) 2005-04-30
CZ2004501A3 (cs) 2004-09-15
HUP0401849A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
NO20032220L (no) Lofteverktoy II og fremgangsmate for anvendelse av samme
NO20025804D0 (no) Testremser som har flere reaksjonssoner og fremgangsmåte for anvendelse ogfremstilling av disse
NO20035685L (no) Metoder og apparat for utviding av ror
NO20034218L (no) Fremgangsmåte og anordning til avkutting av undervannsstrukturer
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20052512D0 (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
FI20021983L (fi) Menetelmä ja järjestelmä laskuoperaatioiden suorittamiseksi ja laite
FI20021984L (fi) Menetelmä ja järjestelmä laskuoperaatioiden suorittamiseksi ja laite
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
NO20044915L (no) C-aryl-glukosid SGLT2 inhibitorer og metode
NO20051493L (no) Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
NO20034038L (no) Fremgangsmåte og anordning for pakking av gjenstander
NO20051875D0 (no) Kjoleror og fremgangsmate for bruk av dette
DK1344451T3 (da) Indretning og opstilling til en dyrerelateret handling
DE60313133D1 (de) System und verfahren zum ausgleich von dynamischem ungleichgewicht
FI20020942A0 (fi) Menetelmä tärkkelyksen käsittelemiseksi
DK1663997T3 (da) 1h-azolyl-methyl-amider, fremgangsmåde til fremstilling deraf og anvendelse deraf som nitrifikationsinhibitorer
NO20031004L (no) Fremgangsmåte og anordning for demodulasjon
FI20030446L (fi) Artikkelin irrotuslaite ja menetelmä sellaisen käyttämiseksi
NO20032045L (no) Fremgangsmåte for hydratisering av gipsplater og anordning for samme
DK1426294T3 (da) Fremgangsmåde og indretning til emballering af flade genstande
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme